18
Participants
Start Date
July 31, 2014
Primary Completion Date
January 31, 2017
Study Completion Date
January 31, 2017
Desvenlafaxine
All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montreal
Collaborators (1)
Pfizer
INDUSTRY
Centre hospitalier de l'Université de Montréal (CHUM)
OTHER